Chronic beryllium disease (CBD) is a granulomatous pulmonary condition arising from beryllium sensitisation. First-line management addresses underlying inflammation while also targeting respiratory complications that affect functional status.
The protocol centres on corticosteroid-sparing immunosuppressive therapy, supported by adjuvant measures to manage airflow obstruction, fluid balance, and hypoxemia. The complete agent selection, sequencing, and supportive care plan is contained in the full protocol.
DOI: 10.1080/15459620903158698
Modeled on the management of sarcoidosis, oral methotrexate, and azathioprine may be used as corticosteroid-sparing agents in CBD.
Adjuvant therapy with bronchodilators and diuretics also should be considered.
Supplemental oxygen may be necessary to correct hypoxemia associated with CBD.
View source ↗